businesspress24.com - Kane Biotech Announces Board Members
 

Kane Biotech Announces Board Members

ID: 1439586

(firmenpresse) - WINNIPEG, MANITOBA -- (Marketwired) -- 06/06/16 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that at the Company''s Annual and Special Meeting of shareholders held on June 2, 2016 (the "Meeting"), the following individuals were elected to the board of directors: Philip Renaud (Chairman), Dr. Arvind Joshi, Mark Nawacki, Dr. Sarah Prichard, Mark Ahrens-Townsend and Marc Edwards. Each Director is to serve for a term of one year or until their successors are elected or appointed.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™ and Coactiv+™ are registered trademarks of Kane Biotech Inc. All Rights Reserved 2016.



Contacts:
Kane Biotech Inc.




Mark Ahrens-Townsend
President and CEO
204-477-7592
204-474-7552 (FAX)

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Fennec Announces Interim Results of SIOPEL 6 Study on Sodium Thiosulfate (STS) Presented at the American Association of Clinical Oncology (ASCO) 2016 Meeting
Arch Therapeutics Completes Patient Enrollment in Clinical Study of AC5
Bereitgestellt von Benutzer: Marketwired
Datum: 06.06.2016 - 06:00 Uhr
Sprache: Deutsch
News-ID 1439586
Anzahl Zeichen: 4924

contact information:
Contact person:
Town:

WINNIPEG, MANITOBA


Phone:

Kategorie:

Alternative


Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:


Diese Pressemitteilung wurde bisher 233 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Kane Biotech Announces Board Members
"
steht unter der journalistisch-redaktionellen Verantwortung von

Kane Biotech Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Kane Biotech Inc.



 

Who is online

All members: 10 565
Register today: 0
Register yesterday: 2
Members online: 0
Guests online: 42


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.